Abcam plc and Cell Marque Corporation have announced that they have signed a global 10-year strategic marketing agreement for Abcam’s in vitro diagnostic (IVD) immunohistochemistry (IHC) RabMAb® primary antibody portfolio.
Under the agreement, Cell Marque will apply its extensive IVD expertise to incorporate Abcam’s IVD IHC RabMAb primary antibodies into its portfolio and use its established distribution channels to distribute them to the global market. The agreement will give customers faster, easier access to Abcam’s high-quality antibodies.
The antibodies use Abcam’s powerful RabMAb technology offering superior binding affinity and specificity, and have been specifically developed to provide high-quality results to pathology laboratories for immunohistochemical staining of formalin-fixed paraffin embedded (FFPE) tissue.
Alan Hirzel, Chief Marketing Officer, Abcam, commented: “We are excited about the growth opportunity that this agreement provides. Part of our strategy is to work with partners that offer complementary high-quality products and who share our vision of enabling researchers to discover more. The agreement with Cell Marque will enable Abcam to extend its reach within the in vitro diagnostics market, with a broader range of customers able to access our in-house developed RabMAb products.”
Nora Lacey, President and CEO of Cell Marque, commented: “The addition of Abcam’s IVD RabMAb products complements our current portfolio. The agreement with Abcam demonstrates Cell Marque’s ability to meet the quality and performance requirements of pathologists and will expand our offering of exceptional quality diagnostic tools.”